Lilly's (LLY.US) oral weight loss drug Phase III data released: average weight loss of 10.5%, will initiate global filing.

According to the Zhitong Financial APP, Eli Lilly (LLY.US) announced on Tuesday that its oral weight loss therapy orforglipron has achieved its main goal in the Phase 3 clinical trial. The company will now proceed with global registration applications for this once-daily GLP-1 receptor agonist.